BGB BGB
Company Profile ↓Company Overview
BGB (BGB) is a publicly traded company listed on with a market capitalization of $487.89M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 8.7.
Maintains a net profit margin of 83.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $35.84M (-41.9% YoY); net profit $30.08M.
- Trailing 12 Months Year-on-year growth — revenue -41.9%, earnings -46.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -41.93% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -46.13% |
Stock Price Performance
| 1 Year: | -0.43% |
| 6 Months: | +0.76% |
| 3 Months: | -1.19% |
| 1 Month: | -1.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 83.9%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | -67.29M | 86.43M | 61.72M | 35.84M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 4.15M | 5.78M | 5.89M | 5.77M |
| Operating Income | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Interest Expense | - | 8.13M | 17.18M | 20.66M | 15.78M |
| Pretax Income | - | -71.44M | 80.65M | 55.83M | 30.08M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -71.44M | 80.65M | 55.83M | 30.08M |
| Diluted EPS | 1.14 | -1.60 | 1.81 | 1.25 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 972.48M | 939.79M | 1.01B | 925.31M |
| Current Assets | - | - | - | - |
| Cash & Equivalents | 50.57M | 557.63K | 456.50K | 293.70K |
| Inventory | - | - | - | - |
| Receivables | 71.72M | 14.16M | 35.56M | 15.34M |
| Total Liabilities | 433.62M | 374.33M | 439.56M | 369.53M |
| Current Liabilities | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Total Debt | 268.90M | 282.60M | 294.00M | 292.20M |
| Total Equity | 538.86M | 565.47M | 570.69M | 555.78M |
| Shares Outstanding | 44.66M | 44.66M | 44.66M | 44.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 137.40M | -13.19M | 39.50M | 47.33M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | -94.56M | -36.83M | -39.60M | -47.49M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | 137.40M | -13.19M | 39.50M | 47.33M |
| Net Change in Cash | - | 42.84M | -50.02M | -101.13K | -162.80K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | 106.2% | 93.3% | 90.5% | 83.9% |
| ROE % | - | -13.3% | 14.3% | 9.8% | 5.4% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BGB
Precision Trading with Blackstone Strategic Credit 2027 Term Fund Of Beneficial Interest (BGB) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMikgJBVV95cUxNSzQ1Skk0cVo3cUNyQ25BTUtiT0NraTgxWmI4bTZqU19xVXdYUnZNSVV2U1hKbGV3Uld4YkY3V3BOSDNGRFd5VnJrLVdTdWloY0t2RThCY1JOcWdMV1FOZjdWR29DTU44V2thTGV6dmdWOHUxLUFNajNOVkRHWXdzUzZVbnBXemFud3oyR3…
Lowest Fee Tokenized Stock Platform: Bitget Fees & Discounts (2026 Guide) - Bitget
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNSjdUVXloQWRRTzc2RTF3N3J1WkNlaUk4bC1qOFZIU2d1bTNWQWJXSmdLVWNEZVRUVHhSWmJoYTNZNkM5V0FqcVFnVDhWMDF4S0VkUklzTDZsRG83WTBpRnhxWGQwMkNoNm9qaHpJc1NSRW9BQjZUaE9vQXpmakV3bWVrTE1PbVladHBPNn…
Blackstone Strategic Credit 2027 Term Fund (BGB) Holds Steady Near $11.29 Amid Modest Gains - Supply Zone - www.dars.gov.et
<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxQLVU1VlJzaVhXdlRtQjFURmh2RE13TDRtSU5nRk5KZFhfbXlKZFpORG5vX3BUdHpzY0hqRkJWbDVJclkyWU4xWlAyVm9oaDJxakZTMDdPOUI5ZEF1WEx1RjBjeTVZT1djRkkxbDA3Rk1lbkozZ3MwVmE5Ukt2V3RVWHhiQ1J0Mk9DMEI0YW…
Blackstone Strategic Credit 2027 Term Fund (BGB) Edges Up 0.27% to $11.13, Holding Mid-Range - MAMA Signal - https://www.siam.in/
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPMjJfVnFnMjlQMEkzdHJza1QtRXkxbFBxWk9KVFpqMnNmTS02cDAwbFhiZDlvQmkxN0FxajctdmJ6alR6c3dvRVA5OUtKOUd5NzMtX3YtWE9UTllHX2VUTjhCVnkwM0J3eklrZkIxdVFlcU1wcjJpTEswdTlWd1ViV1JKMUNNWDFYcmZpWU…
BTK Degrader BGB-16673 Shows Promise in R/R WM and CLL/SLL - CancerNetwork
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQNnlaRXVpaXBYZjlTVkNDSDF3bVBNR2pqSmpIM3NCOHhnc1VzdWdScHo3SHh2cDA2OUZxbEtmSk1MemJFMG1iNnlVRVg0LV9uQkYxbl94M1dSaGJObk1tVklaS0ZLejN5c1VVV2R1STZZNUM1TTBNczNaVXdPR2E5dWRfdU1VS2pZZklIYn…
EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia - OncLive
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxORlkzY0FxMFFJQWhWODBucS1rSl9oalU0VzN0MkxYWS12ejdlaHZreE1aY2ladzZxLS1TbzBKZmh0U1I5Mzhkam55UEE4bERUdGVFMWlseVhCTTIzY1lPaW9md1EtZGNwWTJ3V25uRjRJLV9QYnlHb2xmVmxsREduNG5vby1zMUVNVktYVF…
BGB — Frequently Asked Questions
What is the current share price of BGB?
As of 2026-10-23 16:27 PDT, BGB trades at $10.92 on NASDAQ/NYSE. Its 52-week range is $10.50 to $11.32.
What is the market capitalisation of BGB?
BGB has a market capitalisation of $487.89M on NASDAQ/NYSE.
What is the P/E ratio of BGB?
BGB trades at a trailing price-to-earnings (P/E) ratio of 8.74. Its price-to-book (P/B) ratio is 0.88.
What is the return on equity (ROE) of BGB?
BGB has a return on equity (ROE) of 5.41%.
Is BGB a good stock to buy?
This page provides a data-driven analysis of BGB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.